Brief: Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform
03/12/2025 13:59
Dec 3 (Reuters) - BioNexus Gene Lab Corp BGLC.O: BIONEXUS GENE LAB CORP. COMPLETES STRATEGIC INVESTMENT IN FIDELION DIAGNOSTICS; SECURES 15% EQUITY STAKE IN GLOBAL AI-ONCOLOGY PLATFORM AND EXCLUSIVE SOUTHEAST ASIAN RIGHTS FOR VITAGUARD™ BIONEXUS GENE LAB CORP - BUYS 15% EQUITY STAKE IN FIDELION DIAGNOSTICS Source text: ID:nGNXbh3Wkd Further company coverage: BGLC.O ((Reuters.Briefs@thomsonreuters.com;))